Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.38 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.38 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.38 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.38 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.38 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.38 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.38 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.38 |
| ▸ | PSMA5 | P28066 | 1/20 | 0.38 |
| ▸ | PSMB4 | P28070 | 1/20 | 0.38 |
| ▸ | PSMB6 | P28072 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2084166 | 0.86 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ATRPV1PDE10A | |
| SCHEMBL2084354 | 0.86 | CYP2D6 (0.41) | SMN1; SMN2TRPV1PSMB11PSMA7PSMB1 | |
| SCHEMBL2084436 | 0.85 | FAAH (0.38) | SMN1; SMN2TRPV1 | |
| SCHEMBL2082964 | 0.85 | POLB (0.41) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2084022 | 0.84 | CXCR4 (0.38) | TRPV1LMNATP53 | |
| SCHEMBL2083283 | 0.83 | CXCR4 (0.39) | TRPV1LMNATP53 | |
| SCHEMBL2085997 | 0.82 | GSK3B (0.36) | TRPV1 | |
| SCHEMBL23428540 | 0.81 | ADRA1D (0.36) | TRPV1 | |
| SCHEMBL2083906 | 0.81 | CXCR4 (0.36) | TRPV1HSD17B10 | |
| SCHEMBL5058354 | 0.81 | CXCR4 (0.39) | MEN1KMT2ALMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863293-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2011-01-04 | — | — | US | claimed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | claimed |
| US-7291631-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2007-11-06 | — | — | US | claimed |
| EP-1613613-B1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORP (US) | 2021-06-02 | — | — | EP | disclosed |
| US-20140140927-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-22 | — | — | US | disclosed |
| US-7863293-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863293-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863293-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | disclosed |
| US-7291631-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291631-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291631-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | ANORMED CORPORATION (CA) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140140927-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | PSEN1, PSEN2, CROCC | SMN1; SMN2 2347/4885NPC1 53/4885RAB9A 1888/4885 |
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | CXCR4, CXCR1, CXCR3 | SMN1; SMN2 4611/4885NPC1 1612/4885RAB9A 899/4885 |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | CXCR4, CXCR1, CXCR3 | SMN1; SMN2 4601/4885NPC1 1188/4885RAB9A 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.